Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.

Since the Novo Nordisk (CSE:NOVOb) share price peaked in June last year ... saw a much-needed comeback of over 10% following the release of promising new data for Amycretin, a drug currently under ...

Manufacturing complexities, particularly for peptide-based drugs like the company's new candidate Amycretin, present ongoing challenges. Novo Nordisk must navigate these complexities to ensure ...

Novo Nordisk, a leading global healthcare company, announced topline results from a phase 1b/2a clinical trial with amycretin, a unimolecular GLP-1 and amylin receptor agonist intended for once weekly ...

Europe's largest pharmaceutical firm, Novo Nordisk, revealed positive trial results for its next-generation obesity drug, amycretin, marking a major step in its competition within the increasingly ...

Bagsværd, Denmark, 24 January 2025 – Novo Nordisk today announced topline results from a phase 1b/2a clinical trial with amycretin, a unimolecular GLP-1 and amylin receptor agonist intended for once ...

The drug, amycretin, is a peptide designed to bind to and activate both the GLP-1 and amylin receptors. Novo Nordisk is developing the molecule for the treatment of obesity and type 2 diabetes ...

Novo Nordisk shares surged on the results of a ... Patients in the trial were given ascending doses of amycretin, a drug that mimics the same gut hormone as Wegovy. Based on Friday’s results ...

Novo Nordisk A/S Bagsværd, Denmark, 24 January 2025 – Novo Nordisk today announced topline results from a phase 1b/2a clinical trial with amycretin, a unimolecular GLP-1 and amylin receptor ...

Novo Nordisk shares rose sharply Friday after the Danish pharmaceutical giant said an experimental weight-loss shot helped patients lose 22% of their body weight in a clinical trial. Shares were 7 ...